- Home
- MUJ vs PHAR Comparison
MUJ vs PHAR Comparison
Compare MUJ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- PHAR
- Stock Information
- Founded
- MUJ 1998
- PHAR 1988
- Country
- MUJ United States
- PHAR Netherlands
- Employees
- MUJ N/A
- PHAR N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- PHAR Health Care
- Exchange
- MUJ Nasdaq
- PHAR Nasdaq
- Market Cap
- MUJ 602.6M
- PHAR 679.0M
- IPO Year
- MUJ N/A
- PHAR N/A
- Fundamental
- Price
- MUJ $11.28
- PHAR $9.09
- Analyst Decision
- MUJ
- PHAR Strong Buy
- Analyst Count
- MUJ 0
- PHAR 3
- Target Price
- MUJ N/A
- PHAR $27.00
- AVG Volume (30 Days)
- MUJ 108.0K
- PHAR 6.6K
- Earning Date
- MUJ 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- MUJ 4.36%
- PHAR N/A
- EPS Growth
- MUJ N/A
- PHAR N/A
- EPS
- MUJ N/A
- PHAR N/A
- Revenue
- MUJ N/A
- PHAR $285,745,000.00
- Revenue This Year
- MUJ N/A
- PHAR $20.08
- Revenue Next Year
- MUJ N/A
- PHAR $9.22
- P/E Ratio
- MUJ N/A
- PHAR N/A
- Revenue Growth
- MUJ N/A
- PHAR 30.64
- 52 Week Low
- MUJ $9.74
- PHAR $6.65
- 52 Week High
- MUJ $11.70
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- MUJ 51.27
- PHAR 46.17
- Support Level
- MUJ $11.21
- PHAR $9.37
- Resistance Level
- MUJ $11.45
- PHAR $10.01
- Average True Range (ATR)
- MUJ 0.10
- PHAR 0.50
- MACD
- MUJ 0.05
- PHAR -0.13
- Stochastic Oscillator
- MUJ 70.00
- PHAR 0.00
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.